NASDAQ:GTHX G1 Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.99 +0.82 (+15.86%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$5.10▼$6.0250-Day Range$4.04▼$5.9952-Week Range$3.84▼$21.62Volume1.15 million shsAverage Volume1.45 million shsMarket Capitalization$255.83 millionP/E RatioN/ADividend YieldN/APrice Target$39.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside545.5% Upside$38.67 Price TargetShort InterestBearish23.33% of Float Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment1.05Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.87) to ($2.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.26 out of 5 starsMedical Sector223rd out of 1,426 stocksPharmaceutical Preparations Industry104th out of 682 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.67, G1 Therapeutics has a forecasted upside of 545.5% from its current price of $5.99.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted23.33% of the float of G1 Therapeutics has been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 6.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 3.4 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for G1 Therapeutics this week, compared to 1 article on an average week.Search Interest19 people have searched for GTHX on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.09% of the stock of G1 Therapeutics is held by insiders.Percentage Held by Institutions61.89% of the stock of G1 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($3.87) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About G1 Therapeutics (NASDAQ:GTHX) StockG1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock News HeadlinesJuly 3, 2022 | americanbankingnews.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Receives $38.67 Consensus PT from BrokeragesJuly 1, 2022 | americanbankingnews.comAnalysts Set G1 Therapeutics, Inc. (NASDAQ:GTHX) Price Target at $38.67June 28, 2022 | finance.yahoo.comG1 Therapeutics Announces Addition of Jacks Lee to Board of DirectorsJune 13, 2022 | finance.yahoo.comG1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal CancerJune 2, 2022 | finance.yahoo.comData Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to ChemotherapyMay 20, 2022 | finance.yahoo.comG1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business JournalMay 18, 2022 | finance.yahoo.comG1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment ConferenceMay 7, 2022 | finance.yahoo.comThe past three years for G1 Therapeutics (NASDAQ:GTHX) investors has not been profitableMay 4, 2022 | seekingalpha.comG1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | seekingalpha.comG1 therapeutics stock falls 8% after Q1 loss widens due to higher costsMay 4, 2022 | finance.yahoo.comG1 Therapeutics Provides First Quarter 2022 Financial Results and Operational HighlightsMay 3, 2022 | seekingalpha.comG1 Therapeutics grants stock options to employeesApril 27, 2022 | finance.yahoo.comEarnings Preview: G1 Therapeutics (GTHX) Q1 Earnings Expected to DeclineApril 27, 2022 | seekingalpha.comG1 Therapeutics: Needs To Expand Labels And Commercialize BetterApril 21, 2022 | finance.yahoo.comG1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022April 6, 2022 | finance.yahoo.comG1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare ConferenceMarch 31, 2022 | tmcnet.comNew Real-World Data Show Potential of TrilaciclibMarch 31, 2022 | finance.yahoo.comNew Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with ChemotherapyMarch 31, 2022 | bizjournals.comSix questions with Incyclix Bio CEO Patrick RobertsMarch 31, 2022 | bizjournals.comRTP startup backed by Eshelman raises $30M ahead of clinical trials for cancer treatmentMarch 7, 2022 | finance.yahoo.comAre Institutions Heavily Invested In G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shares?February 23, 2022 | finance.yahoo.comG1 Therapeutics, Inc. (GTHX) Q4 2021 Earnings Call TranscriptFebruary 23, 2022 | finance.yahoo.comG1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsFebruary 23, 2022 | finance.yahoo.comG1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue EstimatesFebruary 22, 2022 | seekingalpha.comG1 Therapeutics Q4 2021 Earnings PreviewSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees148Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/05/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$38.67 High Stock Price Forecast$67.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+556.6%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,350,000.00 Net Margins-708.20% Pretax Margin-704.95% Return on Equity-107.75% Return on Assets-68.95% Debt Debt-to-Equity Ratio0.76 Current Ratio5.96 Quick Ratio5.73 Sales & Book Value Annual Sales$31.48 million Price / Sales8.13 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book1.77Miscellaneous Outstanding Shares42,710,000Free Float39,251,000Market Cap$255.83 million OptionableOptionable Beta1.90 G1 Therapeutics Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" G1 Therapeutics stock. View analyst ratings for G1 Therapeutics or view top-rated stocks. What is G1 Therapeutics' stock price forecast for 2022? 6 equities research analysts have issued 12-month price objectives for G1 Therapeutics' stock. Their GTHX stock forecasts range from $19.00 to $67.00. On average, they expect G1 Therapeutics' stock price to reach $38.67 in the next year. This suggests a possible upside of 545.5% from the stock's current price. View analysts' price targets for G1 Therapeutics or view top-rated stocks among Wall Street analysts. How has G1 Therapeutics' stock performed in 2022? G1 Therapeutics' stock was trading at $10.21 at the beginning of 2022. Since then, GTHX stock has decreased by 41.3% and is now trading at $5.99. View the best growth stocks for 2022 here. When is G1 Therapeutics' next earnings date? G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for G1 Therapeutics. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.16. The business had revenue of $6.90 million for the quarter, compared to analyst estimates of $5.78 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 107.75% and a negative net margin of 708.20%. During the same quarter in the previous year, the firm earned ($0.65) EPS. View G1 Therapeutics' earnings history. Who are G1 Therapeutics' key executives? G1 Therapeutics' management team includes the following people: Mr. John E. Bailey Jr., CEO, Pres & Director (Age 57, Pay $1.04M)Ms. Jennifer K. Moses CPA, Chief Financial Officer (Age 47, Pay $606.27k)Dr. Mark A. Velleca M.D., Ph.D., Sr. Advisor & Director (Age 58, Pay $242.69k) (LinkedIn Profile)Dr. Rajesh K. Malik Ch.B., M.B., M.D., Chief Medical Officer and Sr. VP of R&D (Age 63, Pay $596.37k)Mr. Mark Avagliano, Chief Bus. Officer (Age 46, Pay $606.05k)Mr. Andrew Perry, Chief Commercial Officer (Age 49, Pay $568.6k)Mr. Terry L. Murdock, Chief Operating Officer (Age 62)Mr. Alexander D. Smith M.S., VP of Technical OperationsDr. Jay C. Strum Ph.D., Chief Scientific Officer (Age 58)Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 53) Who are some of G1 Therapeutics' key competitors? Some companies that are related to G1 Therapeutics include MannKind (MNKD), Rocket Pharmaceuticals (RCKT), I-Mab (IMAB), Amneal Pharmaceuticals (AMRX), CannTrust (CNTTF), Chinook Therapeutics (KDNY), Crinetics Pharmaceuticals (CRNX), Amneal Pharmaceuticals (AMRX), Merus (MRUS), BELLUS Health (BLU), Procaps Group (PROC), uniQure (QURE), Avid Bioservices (CDMO), Belite Bio (BLTE) and SIGA Technologies (SIGA). View all of GTHX's competitors. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." How do I buy shares of G1 Therapeutics? Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $5.99. How much money does G1 Therapeutics make? G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $255.81 million and generates $31.48 million in revenue each year. The company earns $-148,350,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. How many employees does G1 Therapeutics have? G1 Therapeutics employs 148 workers across the globe. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for G1 Therapeutics is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830. This page (NASDAQ:GTHX) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
